Exopharm Past Earnings Performance
Past criteria checks 0/6
Exopharm's earnings have been declining at an average annual rate of -22.5%, while the Biotechs industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 41.6% per year.
Key information
-22.5%
Earnings growth rate
-3.2%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 41.6% |
| Return on equity | -172.8% |
| Net Margin | -210.1% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Will Exopharm (ASX:EX1) Spend Its Cash Wisely?
May 27
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Oct 20Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Jul 02Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Apr 03Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%
Feb 09
Revenue & Expenses BreakdownBeta
How Exopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 3 | -7 | 7 | 0 |
| 31 Mar 23 | 5 | -7 | 8 | 0 |
| 31 Dec 22 | 6 | -7 | 9 | 0 |
| 30 Sep 22 | 5 | -9 | 10 | 0 |
| 30 Jun 22 | 4 | -10 | 10 | 0 |
| 31 Mar 22 | 4 | -10 | 10 | 0 |
| 31 Dec 21 | 4 | -10 | 10 | 0 |
| 30 Sep 21 | 4 | -9 | 9 | 0 |
| 30 Jun 21 | 4 | -8 | 8 | 0 |
| 31 Mar 21 | 3 | -8 | 8 | 0 |
| 31 Dec 20 | 3 | -7 | 7 | 0 |
| 30 Sep 20 | 3 | -6 | 6 | 0 |
| 30 Jun 20 | 3 | -5 | 5 | 0 |
| 31 Mar 20 | 1 | -5 | 4 | 0 |
| 31 Dec 19 | 0 | -5 | 3 | 0 |
| 30 Sep 19 | 0 | -4 | 2 | 0 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 30 Jun 16 | 0 | 0 | 0 | 0 |
Quality Earnings: EX1 is currently unprofitable.
Growing Profit Margin: EX1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EX1 is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare EX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EX1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: EX1 has a negative Return on Equity (-172.77%), as it is currently unprofitable.